The association between preoperative COVID-19-positivity and acute postoperative complication risk among patients undergoing orthopedic surgery.

Aims: This study aimed to investigate the risk of postoperative complications in COVID-19-positive patients undergoing common orthopaedic procedures. Methods: Using the National Surgical Quality Improvement Programme (NSQIP) database, patients who underwent common orthopaedic surgery procedures from 1 January to 31 December 2021 were extracted. Patient preoperative COVID-19 status, demographics, comorbidities, type of surgery, and postoperative complications were analyzed. Propensity score matching was conducted between COVID-19-positive and -negative patients. Multivariable regression was then performed to identify both patient and provider risk factors independently associated with the occurrence of 30-day postoperative adverse events. Results: Of 194,121 included patients, 740 (0.38%) were identified to be COVID-19-positive. Comparison of comorbidities demonstrated that COVID-19-positive patients had higher rates of diabetes, heart failure, and pulmonary disease. After propensity matching and controlling for all preoperative variables, multivariable analysis found that COVID-19-positive patients were at increased risk of several postoperative complications, including: any adverse event, major adverse event, minor adverse event, death, venous thromboembolism, and pneumonia. COVID-19-positive patients undergoing hip/knee arthroplasty and trauma surgery were at increased risk of 30-day adverse events. Conclusion: COVID-19-positive patients undergoing orthopaedic surgery had increased odds of many 30-day postoperative complications, with hip/knee arthroplasty and trauma surgery being the most high-risk procedures. These data reinforce prior literature demonstrating increased risk of venous thromboembolic events in the acute postoperative period. Clinicians caring for patients undergoing orthopaedic procedures should be mindful of these increased risks, and attempt to improve patient care during the ongoing global pandemic.

Topical tranexamic acid reduces transfusion rates in simultaneous bilateral total knee arthroplasty: a retrospective case series.

BACKGROUND: Topical tranexamic acid (TA) has been reported to be effective in reducing postoperative bleeding and transfusions after total knee arthroplasty (TKA). The main objective of this study was to retrospectively assess the effectiveness and safety of topical TA administration in patients undergoing simultaneous bilateral TKA. METHODS: We conducted a retrospective chart review of consecutive cohorts of patients undergoing simultaneous bilateral TKA. We compared the patients who received TA with patients from a similar time frame who did not receive TA. For those who received TA, a topical concentration of 2 g per 30 mL of normal saline was used in each knee. Preoperative and postoperative hemoglobin, transfusions, length of stay (LOS) and postoperative complications were recorded for each patient until discharge. Outcome measures were analyzed using independent t test, χ2 test and logistic regression. RESULTS: We included 49 patients in our analysis: 25 who received TA and 24 who did not. There were no statistical differences in demographics between the groups. The rate of transfusion in the TA group was 4% compared with 67% in the non-TA group (p < 0.001). The net hemoglobin loss in the TA group was 4.1 g/dL versus 6.2 g/dL in the non-TA group (p < 0.001). The use of TA was found to be associated with a greater than 99% reduced risk of receiving a transfusion (odds ratio 0.003, 95% confidence interval < 0.001-0.072, p < 0.001). There were no thromboembolic events in patients who received TA, and there was 1 pulmonary embolus in the non-TA group. Postoperative LOS was significantly reduced in the TA group (mean difference 1.1 d, p = 0.005). CONCLUSION: Topical administration of TA in patients undergoing simultaneous bilateral TKA significantly reduced transfusions, blood loss and postoperative LOS, with no increased risk of thromboembolic events.

CONTEXTE: Selon certains rapports, l'acide tranexamique (AT) topique réduirait efficacement les saignements postopératoires et le recours aux transfusions après une intervention pour prothèse totale du genou. Le principal objectif de cette étude était d'évaluer de manière rétrospective l'efficacité et l'innocuité de l'AT topique chez des patients soumis à une intervention pour prothèse totale des 2 genoux. MÉTHODES: Nous avons procédé à une analyse rétrospective des dossiers de cohortes consécutives de patients soumis à une intervention pour prothèse totale des 2 genoux. Nous avons comparé les patients ayant reçu l'AT aux patients d'une période similaire qui n'ont pas reçu l'AT. Pour ceux qui ont reçu l'AT, la concentration topique de 2 g par 30 mL de solution physiologique a été utilisée dans les 2 genoux. On a enregistré chez chaque patient les taux d'hémoglobine pré- et postopératoires, le nombre de transfusions, la durée du séjour hospitalier et les complications postopératoires jusqu'à leur congé. Les paramètres ont été analysés à l'aide du test t, du test du χ2 et de la régression logistique. RÉSULTATS: Nous avons inclus 49 patients dans notre analyse : 25 ayant reçu l'AT et 24 ne l'ayant pas reçu. Il n'y avait aucune différence statistique entre les groupes pour ce qui est des caractéristiques démographiques. Le taux de transfusions dans le groupe ayant reçu l'AT a été de 4 %, contre 67 % dans le groupe n'ayant pas reçu l'AT (p < 0,001). La baisse nette de l'hémoglobine dans le groupe ayant reçu l'AT a été de 4,1 g/dL, contre 6,2 g/dL dans le groupe n'ayant pas reçu l'AT (p < 0,001). L'utilisation de l'AT a été associée à une réduction de plus de 99 % du risque de transfusion (rapport des cotes 0,003, intervalle de confiance de 95 % < 0,001-0,072, p < 0,001). On n'a noté aucun incident thromboembolique chez les patients ayant reçu l'AT, et une embolie pulmonaire dans le groupe n'ayant pas reçu l'AT. La durée du séjour hospitalier postopératoire a été significativement plus brève dans le groupe ayant reçu l'AT (différence moyenne 1,1 j, p = 0,005). CONCLUSION: L'administration topique d'AT chez des patients soumis à une intervention pour prothèse totale des 2 genoux a significativement réduit le recours aux transfusions et les pertes sanguines et a abrégé les séjours hospitaliers postopératoires, sans accroître le risque d'incidents thromboemboliques.

Use of fresh osteochondral glenoid allograft to treat posteroinferior bone loss in chronic posterior shoulder instability.

We report our experience with the use of fresh glenoid osteochondral allograft in the treatment of a chronic posttraumatic posterior subluxation of the shoulder associated with glenoid bone loss in a 54-year-old recreational football player. Based on the pathoanatomy of the lesion and availability of a bone bank providing fresh allograft, we opted for an open anatomic reconstruction using a fresh glenoid allograft. A posterior approach was used; the prepared allograft was placed in the appropriate anatomic position and fixed with 2 small fragment screws with washers. At 2-year follow-up, the clinical outcome is excellent. This procedure may represent an effective option for the treatment of chronic posterior shoulder instability due to glenoid bone loss. However, the long-term efficacy and the progression of glenohumeral osteoarthritis need to be evaluated.

Integration of tissue-engineered cartilage with host cartilage: an in vitro model.

BACKGROUND: We developed a tissue-engineered biphasic cartilage bone substitute construct which has been shown to integrate with host cartilage and differs from autologous osteochondral transfer in which integration with host cartilage does not occur. QUESTIONS/PURPOSES: (1) Develop a reproducible in vitro model to study the mechanisms regulating tissue-engineered cartilage integration with host cartilage, (2) compare the integrative properties of tissue-engineered cartilage with autologous cartilage and (3) determine if chondrocytes from the in-vitro formed cartilage migrate across the integration site. METHODS: A biphasic construct was placed into host bovine osteochondral explant and cultured for up to 8 weeks (n = 6 at each time point). Autologous osteochondral implants served as controls (n = 6 at each time point). Integration was evaluated histologically, ultrastructurally, biochemically and biomechanically. Chondrocytes used to form cartilage in vitro were labeled with carboxyfluorescein diacetate which allowed evaluation of cell migration into host cartilage. RESULTS: Histologic assessment demonstrated that tissue-engineered cartilage integrated over time, unlike autologous osteochondral implant controls. Biochemically there was an increase in collagen content of the tissue-engineered implant over time but was well below that for native cartilage. Integration strength increased between 4 and 8 weeks as determined by a pushout test. Fluorescent cells were detected in the host cartilage up to 1.5 mm from the interface demonstrating chondrocyte migration. CONCLUSIONS: Tissue-engineered cartilage demonstrated improved integration over time in contrast to autologous osteochondral implants. Integration extent and strength increased with culture duration. There was chondrocyte migration from tissue-engineered cartilage to host cartilage. CLINICAL RELEVANCE: This in vitro integration model will allow study of the mechanism(s) regulating cartilage integration. Understanding this process will facilitate enhancement of cartilage repair strategies for the treatment of chondral injuries.